Protagenic Therapeutics, Inc.
PTIX
$3.51
$0.4514.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.76M | 1.22M | 1.24M | 1.09M | 1.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.70M | 5.27M | 6.05M | 5.53M | 4.53M |
| Operating Income | -5.70M | -5.27M | -6.05M | -5.53M | -4.53M |
| Income Before Tax | -5.53M | -5.65M | -6.40M | -6.01M | -5.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.53 | -5.65 | -6.40 | -6.01 | -5.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.53M | -5.65M | -6.40M | -6.01M | -5.00M |
| EBIT | -5.70M | -5.27M | -6.05M | -5.53M | -4.53M |
| EBITDA | -5.65M | -5.21M | -6.00M | -5.49M | -4.50M |
| EPS Basic | -16.00 | -17.83 | -20.36 | -19.21 | -16.09 |
| Normalized Basic EPS | -10.21 | -10.24 | -11.82 | -10.76 | -8.80 |
| EPS Diluted | -16.02 | -17.84 | -20.38 | -19.24 | -16.16 |
| Normalized Diluted EPS | -10.21 | -10.24 | -11.82 | -10.76 | -8.80 |
| Average Basic Shares Outstanding | 1.40M | 1.27M | 1.26M | 1.25M | 1.24M |
| Average Diluted Shares Outstanding | 1.40M | 1.27M | 1.26M | 1.25M | 1.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |